Worth reading
47Recurring
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
13.9
% (year-on-year decline in operating income)Wording
Conditional
How definitive the wording is.Results for this period
Third quarter2024年6月1日〜2025年2月28日ConsolidatedJapanese GAAPNet Sales47,552¥ millionYear on year +4.8%Progress 70.6%
Operating profit714¥ millionYear on year -13.9%Progress 92.6%
Ordinary income759¥ millionYear on year -12.8%Progress 92.4%
Net income attributable to owners of the parent461¥ millionYear on year +4.3%Progress 90.6%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥186.71
Financial position at period-end
Total assets25,622¥ million
of which net assets 8,718 ¥ millionEquity ratio 34.0%vs. prior year-end +1.8pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenueMedical device sales ¥47,546 million (YoY +4.8%), Medical Equipment Manufacturing and Sales ¥169 million (YoY -19.1%), Medical Mall Business ¥53 million (YoY +4.8%)
Segment profitMedical device sales ¥1,615 million (YoY -3.3%), Medical Equipment Manufacturing and Sales ¥-114 million, Medical Mall Business ¥1 million (YoY +59.3%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥67,319 million (YoY +9.4%)
Operating profit¥771 million (YoY -20.2%)
Ordinary income¥821 million (YoY -19.5%)
Net income¥509 million (YoY -12.2%)
Annual Dividend Forecast¥70 → ¥61
Factors Behind Changes in Business Performance
放射線機器等の設備投資需要の増加、検査・手術件数の増加により売上高が増加した一方、賃上げによる人件費の増加、物流コスト上昇、開発中の超音波画像診断装置「ブレストスキャン」に係る研究開発費の計上などで販売費及び一般管理費が増加した。前年同期に計上された減損損失による特別損失が今期は発生しなかったため、親会社株主に帰属する四半期純利益は増加した。
Disclosure regarding the going concern assumption
No applicable matters
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew 1 / Name of newly added company Microsonic Corporation / Excluded 0 / Excluded Company Name Not disclosed
Impairment loss¥0 million
Breakdown of extraordinary income (loss)Extraordinary income Reversal of allowance for doubtful accounts ¥36 million / Extraordinary loss Loss on step acquisition ¥3 million
Depreciation and amortization¥130 million
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingWhether applicable No / Subject person Not disclosed
Issued Shares at Period-End2,553,000 Shares
Treasury Shares at Period-End86,914 Shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2024年6月1日〜2025年2月28日 |
| Net Sales | ¥47,552 million (YoY +4.8%) |
| Operating profit | ¥714 million (YoY -13.9%) |
| Ordinary income | ¥759 million (YoY -12.8%) |
| Profit attributable to owners of the parent | ¥461 million (YoY +4.3%) |
| Net income per share | ¥186.71 |
| Equity ratio | End of the current fiscal period 34 / End of previous period 32.2 |
| Total assets | ¥25,622 million |
| Net assets | ¥8,718 million |
| Full-year earnings forecast | Net Sales ¥67,319 million (YoY +9.4%) / Operating profit ¥771 million (YoY -20.2%) / Ordinary income ¥821 million (YoY -19.5%) / Net income ¥509 million (YoY -12.2%) |
| Annual Dividend Forecast | ¥70 → ¥61 |
| Segment revenue | Medical device sales ¥47,546 million (YoY +4.8%), Medical Equipment Manufacturing and Sales ¥169 million (YoY -19.1%), Medical Mall Business ¥53 million (YoY +4.8%) |
| Segment profit | Medical device sales ¥1,615 million (YoY -3.3%), Medical Equipment Manufacturing and Sales ¥-114 million, Medical Mall Business ¥1 million (YoY +59.3%) |
| Depreciation and amortization | ¥130 million |
| Impairment loss | ¥0 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Reversal of allowance for doubtful accounts ¥36 million / Extraordinary loss Loss on step acquisition ¥3 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 1 / Name of newly added company Microsonic Corporation / Excluded 0 / Excluded Company Name Not disclosed |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 2,553,000 Shares |
| Treasury Shares at Period-End | 86,914 Shares |
| Factors Behind Changes in Business Performance | 放射線機器等の設備投資需要の増加、検査・手術件数の増加により売上高が増加した一方、賃上げによる人件費の増加、物流コスト上昇、開発中の超音波画像診断装置「ブレストスキャン」に係る研究開発費の計上などで販売費及び一般管理費が増加した。前年同期に計上された減損損失による特別損失が今期は発生しなかったため、親会社株主に帰属する四半期純利益は増加した。 |
Items this document does not state (11)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodRevision to Earnings ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.放射線機器などの設備投資需要や検査・手術件数の増加で売上高は増加したが、賃上げによる人件費、物流コスト、開発中製品の研究開発費などの販売費及び一般管理費が増加したため、営業利益と経常利益が減少した。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.